Designing Disruptive Business Models For Unmet Medical Need
An Interview With In Vivo Rising Leader Michael Hufford
An undergraduate class in abnormal psychology and a lifelong interest in technology helped to set Michael Hufford on a career path that now includes the co-founding of five companies. As CEO of Harm Reduction Therapeutics, a nonprofit pharmaceutical company, Hufford hopes to make a cheap, OTC version of naloxone widely available to help prevent unnecessary deaths from opioid overdoses.
You may also be interested in...
Investment and research into the science of aging – and therapeutics that could slow down or even reverse the aging process – are ramping up. Past clinical failures have given way to new and focused approaches that aim to lengthen “healthspan,” turning the last years of life into the best years of life.
Plus deals involving AbbVie/Mitokinin, Roivant/Silicon Therapeutics, CASI/Cleave Therapeutics, Tallac/ALX Oncology, AgeX/LyGenesis, Chinook/Evotec and more.
Seeking to improve on cumbersome, unreliable paper diaries for capturing patient experience data in pharmaceutical clinical trials, Invivodata is integrating Palm computing with a scientific, subject-centered approach to data collection that relies on repeated samplings to focus on the patient's current, immediate state in his or her natural environment.